Do not administer intravenously. Do not administer intramuscularly. Do not administer to lambs weighing less than 15 kg.
Do not administer to primates. Do not administer to pigs. Do not administer to horses and donkeys. Do not administer to goats.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Adverse reactions
Occasionally, a soft diffuse swelling may occur at the injection site but this disappears within five to eight days. In rare cases, recumbency, incoordination and convulsions have been observed.
Deaths of cattle have been observed following a single intravenous dose of 5 mg/kg, and following the subcutaneous injection of doses of 150 mg/kg at 72 hour intervals. In pigs, intramuscular injection at 20 mg/kg has caused deaths. Sheep have died following a single intravenous injection of 7.5 mg/kg bodyweight.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Special precautions for use in animals
Sheep: The clinical trials did not demonstrate a bacteriological cure in sheep with acute mastitis caused by Staphyloccocus aureus and Mycoplasma agalactiae. Do not administer to lambs weighing less than 15 kg since there is a risk of overdose toxicity. Accurate weighing of lambs is important to avoid overdose. The use of a 2 ml or smaller syringe improves accurate dosing.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
INJECTION OF THIS DRUG IN HUMANS CAN BE FATAL - EXERCISE EXTREME CAUTION TO AVOID ACCIDENTAL SELF-INJECTION AND FOLLOW THE ADMINISTRATION INSTRUCTIONS AND THE GUIDANCE BELOW, PRECISELY This product should only be administered by a veterinary surgeon. Never carry a syringe loaded with MILBOTYL 300 mg/ml SOLUTION FOR INJECTION with the needle attached. The needle should be connected to the syringe only when filling the syringe or administering the injection. Keep the syringe and needle separate at all other times. Do not use automatic injection equipment. Ensure that animals are properly restrained, including those in the vicinity. Do not work alone when using MILBOTYL 300 mg/ml SOLUTION FOR INJECTION. In case of human injection SEEK IMMEDIATE MEDICAL ATTENTION and take the vial or the package leaflet with you. Apply a cold pack (not ice) directly to the injection site. |
Additional operator safety warnings
Avoid contact with eyes. Rinse any splashes from skin or eyes immediately with water.
May cause sensitisation by skin contact. Wash hands after use.
Note to the physician
INJECTION OF THIS DRUG IN HUMANS HAS BEEN ASSOCIATED WITH FATALITIES The cardiovascular system is the target of toxicity, and this toxicity may be due to calcium channel blockade. Administration of intravenous calcium chloride should only be considered if there is positive confirmation of exposure to tilmicosin. In dog studies, tilmicosin induced a negative inotropic effect with consequent tachycardia, and a reduction in systemic arterial blood pressure and arterial pulse pressure. DO NOT GIVE ADRENALIN OR BETA-ADRENERGIC ANTAGONISTS SUCH AS PROPRANOLOL. In pigs, tilmicosin-induced lethality is potentiated by adrenalin. In dogs, treatment with intravenous calcium chloride showed a positive effect on the left ventricular inotropic state and some improvements in vascular blood pressure and tachycardia. Pre-clinical data and an isolated clinical report suggest that calcium chloride infusion may help to reverse tilmicosin induced changes in blood pressure and heart rate in humans. Administration of dobutamine should also be considered due to its positive inotropic effects although it does not influence tachycardia. As tilmicosin persists in tissues for several days, the cardiovascular system should be closely monitored and supportive treatment provided. Physicians treating patients exposed to this compound are advised to discuss clinical management with the National Poison Information Service on: 018379964 (IE) or 0844 892 0111(UK). |
Pregnancy
The safety of the veterinary medicinal product has not been established during pregnancy. Use only according to the benefit/risk assessment by the responsible veterinarian.
Interactions with other medicinal products and other forms of interaction
Interactions between macrolides and ionophores have been observed in some species.
Overdose (symptoms, emergency procedures, antidotes)
In cattle subcutaneous injections of 10, 30 and 50 mg/kg body weight, repeated three times with a 72 hours interval, did not cause death. As expected, oedema developed at the site of injection. The only lesion observed at autopsy was a necrosis of the myocardium in the group treated with 50 mg/kg body weight. Doses of 150 mg/kg body weight, administered subcutaneously with an interval of 72 hours caused death. Oedema at the site of injection was observed and at autopsy a light necrosis of the myocardium was the only lesion determined. Other symptoms observed were: difficulty in moving, reduced appetite and tachycardia. In sheep single injections (approximately 30 mg/kg body weight) may cause a slight increase of the rate of respiration.
Higher doses (150 mg/kg body weight) caused ataxia, lethargy and the inability to raise the head. Deaths occurred after one intravenous injection of 5 mg/kg body weight in cattle and 7.5 mg/kg body weight in sheep.
Incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products
Withdrawal periods
Cattle: Meat and offal: 70 days. Milk: 36 days
If the product is administered to cows during the dry period or to pregnant dairy heifers, milk should not be used for human consumption until 36 days after calving.
Sheep: Meat and offal: 42 days. Milk: 18 days
If the product is administered to ewes during the dry period or to pregnant ewes, milk should not be used for human consumption until 18 days after lambing.